Research and Therapeutic Advances of 26S Proteasome Subunit
in Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2025.106.13
- Author:
Chenrui MOU
1
;
Shaotong ZOU
2
;
Chao REN
1
;
Zihan YI
1
;
Jianlin SHI
1
Author Information
1. Department of Chest Surgery, The Third Affiliated Hospital of Kunming Medical University, Yunnan Tumor Hospital,
Kunming 650118, China.
2. Kunming Medical University, Kunming 650032, China.
- Publication Type:English Abstract
- Keywords:
19S regulatory particle;
20S core particle;
26S proteasome subunits;
Lung neoplasms
- MeSH:
Humans;
Proteasome Endopeptidase Complex/chemistry*;
Carcinoma, Non-Small-Cell Lung/genetics*;
Lung Neoplasms/genetics*;
Animals;
Proteasome Inhibitors/therapeutic use*;
Antineoplastic Agents/therapeutic use*
- From:
Chinese Journal of Lung Cancer
2025;28(5):363-370
- CountryChina
- Language:Chinese
-
Abstract:
Lung cancer is one of the most common cancers worldwide and is the leading cause of cancer deaths. Lung adenocarcinoma is the most common type of lung cancer. Due to the lack of effective biomarkers and therapeutic targets in the proliferation and metastasis of lung adenocarcinoma, the overall treatment of lung adenocarcinoma is not optimistic. Therefore, there is a need to find new ideas and methods for lung adenocarcinoma treatment. The 26S proteasome is a multiprotein complex responsible for degrading misfolded proteins and maintaining intracellular protein homeostasis. During the development of non-small cell lung cancer (NSCLC), the regulatory granule subunit of the 26S proteasome promotes the malignant progression of tumours by regulating tumour-associated proteins, immune cells, and related signalling pathways. The proteasome core particle is a key subunit for degrading proteins, and its inhibitors have shown promising anti-tumour effects when combined with conventional chemotherapeutic agents. However, limited by toxic side effects and tumour heterogeneity, targeted inhibitors against the 26S proteasome are still not widely used in NSCLC treatment. This article reviews the mechanism of action and related therapeutic research of 26S proteasome regulatory particle subunits and core particle subunits in NSCLC, and explores the potential of these inhibitors in clinical application.
.
